person · Reporting owner
Casdin Partners FO1-MSV, LP
Disclosed activity across 2 companies
Sign in to followReported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| GeneDx Holdings Corp.WGS · Entity 1634 | Director | June 03, 2024 | June 05, 2024 |
| STANDARD BIOTOOLS INC.LAB · Entity 6116 | Director | June 18, 2024 | June 22, 2024 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
GeneDx Holdings Corp.
Report date June 03, 2024 · Filed June 05, 2024
Jointly reported with Casdin Capital, LLC, Casdin Eli, Casdin Partners Master Fund, L.P., Casdin Partners GP, LLC
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Class A Common StockSEC Table I · non-derivative | Direct | 3,063,509 |
Reported balance
After 2024-06-03 transaction · row 1
Holding and transaction disclosures are not merged.
1 source rowRow 1 · 2024-06-03 · Purchase · Acquired 100,000 · Balance 3,063,509 F1: The price reported in Column 4 is a weighted average price. These shares were bought in multiple transactions within the range of $20.6824 to $20.9659. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares bought at each separate price within the range set forth in this footnote. F2: The securities are owned directly by Casdin Partners Master Fund, L.P. (the "Master Fund") and may be deemed to be indirectly beneficially owned by (i) Casdin Capital, LLC, the investment adviser to the Master Fund ("Casdin"), (ii) Casdin Partners GP, LLC, the general partner of the Master Fund (the "GP"), and (iii) Eli Casdin, the managing member of Casdin and the GP. |
| Class A Common StockSEC Table I · non-derivative | Direct | 3,093,509 |
Reported balance
After 2024-06-04 transaction · row 2
Holding and transaction disclosures are not merged.
1 source rowRow 2 · 2024-06-04 · Purchase · Acquired 30,000 · Balance 3,093,509 F3: The price reported in Column 4 is a weighted average price. These shares were bought in multiple transactions within the range of $21.8623 to $22.8427. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares bought at each separate price within the range set forth in this footnote. F2: The securities are owned directly by Casdin Partners Master Fund, L.P. (the "Master Fund") and may be deemed to be indirectly beneficially owned by (i) Casdin Capital, LLC, the investment adviser to the Master Fund ("Casdin"), (ii) Casdin Partners GP, LLC, the general partner of the Master Fund (the "GP"), and (iii) Eli Casdin, the managing member of Casdin and the GP. |
| Class A Common StockSEC Table I · non-derivative | Direct | 3,142 |
Reported balance
Holding disclosure · report date 2024-06-03 · row 3
Holding and transaction disclosures are not merged.
1 source rowRow 3 · Balance 3,142 F4: The securities are owned directly by Eli Casdin. |
| Class A Common StockSEC Table I · non-derivative | IndirectSee footnote | 432,902 |
Reported balance
Holding disclosure · report date 2024-06-03 · row 4
Holding and transaction disclosures are not merged.
1 source rowRow 4 · Balance 432,902 F5: The securities are owned directly by Casdin Partners FO1-MSV, LP ("Casdin FO1") and may be deemed to be indirectly beneficially owned by (i) Casdin, the investment adviser to Casdin FO1, (ii) the GP, the general partner of Casdin FO1, and (iii) Eli Casdin, the managing member of Casdin Capital, LLC and Casdin Partners GP, LLC. |
| Class A Common StockSEC Table I · non-derivative | IndirectSee footnote | 333,144 |
Reported balance
Holding disclosure · report date 2024-06-03 · row 5
Holding and transaction disclosures are not merged.
1 source rowRow 5 · Balance 333,144 F6: The securities are owned directly by CMLS Holdings LLC ("CMLS Holdings"). The Board of Managers of CMLS Holdings includes Eli Casdin, who, as a member of the Board of Managers of CMLS Holdings, shares voting and investment discretion with respect to the common stock held by CMLS Holdings. |
Filing footnotes · ownership attribution and instrument terms
F1: The price reported in Column 4 is a weighted average price. These shares were bought in multiple transactions within the range of $20.6824 to $20.9659. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares bought at each separate price within the range set forth in this footnote.
F2: The securities are owned directly by Casdin Partners Master Fund, L.P. (the "Master Fund") and may be deemed to be indirectly beneficially owned by (i) Casdin Capital, LLC, the investment adviser to the Master Fund ("Casdin"), (ii) Casdin Partners GP, LLC, the general partner of the Master Fund (the "GP"), and (iii) Eli Casdin, the managing member of Casdin and the GP.
F3: The price reported in Column 4 is a weighted average price. These shares were bought in multiple transactions within the range of $21.8623 to $22.8427. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares bought at each separate price within the range set forth in this footnote.
F4: The securities are owned directly by Eli Casdin.
F5: The securities are owned directly by Casdin Partners FO1-MSV, LP ("Casdin FO1") and may be deemed to be indirectly beneficially owned by (i) Casdin, the investment adviser to Casdin FO1, (ii) the GP, the general partner of Casdin FO1, and (iii) Eli Casdin, the managing member of Casdin Capital, LLC and Casdin Partners GP, LLC.
F6: The securities are owned directly by CMLS Holdings LLC ("CMLS Holdings"). The Board of Managers of CMLS Holdings includes Eli Casdin, who, as a member of the Board of Managers of CMLS Holdings, shares voting and investment discretion with respect to the common stock held by CMLS Holdings.
STANDARD BIOTOOLS INC.
Report date June 18, 2024 · Filed June 22, 2024
Jointly reported with Casdin Partners Master Fund, L.P., Casdin Capital, LLC, Casdin Partners GP, LLC, Casdin Private Growth Equity Fund II, L.P., Casdin Private Growth Equity Fund II GP, LLC, Casdin Private Growth Equity Fund, L.P., CASDIN PRIVATE GROWTH EQUITY FUND GP, LLC, Casdin Eli
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | IndirectSee footnote. | 46,730,821 |
Reported balance
After 2024-06-18 transaction · row 1
Holding and transaction disclosures are not merged.
1 source rowRow 1 · 2024-06-18 · Other · Acquired 655,000 · Balance 46,730,821 F1: Represents a cross-trade, pursuant to which Casdin Partners FO1-MSV, LP ("Casdin FO1") transferred 655,000 shares of Common Stock to Casdin Partners Master Fund, L.P. (the "Master Fund"). F2: The securities are owned directly by the Master Fund and may be deemed to be indirectly beneficially owned by (i) Casdin Capital, LLC, the investment adviser to the Master Fund ("Casdin"), (ii) Casdin Partners GP, LLC, the general partner of the Master Fund (the "GP"), and (iii) Eli Casdin, the managing member of Casdin and the GP. |
| Common StockSEC Table I · non-derivative | IndirectSee footnote. | 545,000 |
Reported balance
After 2024-06-18 transaction · row 2
Holding and transaction disclosures are not merged.
1 source rowRow 2 · 2024-06-18 · Other · Acquired 545,000 · Balance 545,000 F3: Represents a cross-trade, pursuant to which Casdin FO1 transferred 545,000 shares of Common Stock to Casdin Amplify Fund, LP ("Amplify"). F4: The securities are owned directly by Amplify and are deemed to be indirectly beneficially owned by (i) Casdin, the investment adviser to Amplify, (ii) the GP, the general partner of Amplify, and (iii) Eli Casdin, the managing member of Casdin Capital, LLC and Casdin Partners GP, LLC. |
| Common StockSEC Table I · non-derivative | IndirectSee footnote. | 0 |
Reported balance
After 2024-06-18 transaction · row 3
Holding and transaction disclosures are not merged.
1 source rowRow 3 · 2024-06-18 · Other · Disposed 1,200,000 · Balance 0 F5: Represents a cross-trade, pursuant to which Casdin FO1 transferred 1,200,000 shares of Common Stock to the Master Fund and Amplify. F6: The securities were owned directly by Casdin FO1 and were deemed to be indirectly beneficially owned by (i) Casdin, the investment adviser to Casdin FO1, (ii) the GP, the general partner of Casdin FO1, and (iii) Eli Casdin, the managing member of Casdin Capital, LLC and Casdin Partners GP, LLC. |
| Common StockSEC Table I · non-derivative | IndirectSee footnote. | 13,939,637 |
Reported balance
Holding disclosure · report date 2024-06-18 · row 4
Holding and transaction disclosures are not merged.
1 source rowRow 4 · Balance 13,939,637 F7: The securities are owned directly by Casdin Private Growth Equity Fund II, L.P. (the "Equity Fund II") and may be deemed to be indirectly beneficially owned by (i) Casdin, the investment adviser to the Equity Fund II, and (ii) Eli Casdin, the managing member of Casdin. |
| Common StockSEC Table I · non-derivative | IndirectSee footnote. | 2,744,219 |
Reported balance
Holding disclosure · report date 2024-06-18 · row 6
Holding and transaction disclosures are not merged.
1 source rowRow 6 · Balance 2,744,219 F9: The securities are owned directly by Casdin Private Growth Equity Fund, L.P. (the "Equity Fund") and may be deemed to be indirectly beneficially owned by (i) Casdin, the investment adviser to the Equity Fund, and (ii) Eli Casdin, the managing member of Casdin. |
| Common StockSEC Table I · non-derivative | IndirectSee footnote. | 3,774,000 |
Reported balance
Holding disclosure · report date 2024-06-18 · row 7
Holding and transaction disclosures are not merged.
1 source rowRow 7 · Balance 3,774,000 F10: The securities are indirectly owned by Eli Casdin who has voting and investment discretion with respect to the securities. |
| Common StockSEC Table I · non-derivative | Direct | 103,556 |
Reported balance
Holding disclosure · report date 2024-06-18 · row 5
Holding and transaction disclosures are not merged.
1 source rowRow 5 · Balance 103,556 F8: The securities are owned directly by Eli Casdin. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents a cross-trade, pursuant to which Casdin Partners FO1-MSV, LP ("Casdin FO1") transferred 655,000 shares of Common Stock to Casdin Partners Master Fund, L.P. (the "Master Fund").
F2: The securities are owned directly by the Master Fund and may be deemed to be indirectly beneficially owned by (i) Casdin Capital, LLC, the investment adviser to the Master Fund ("Casdin"), (ii) Casdin Partners GP, LLC, the general partner of the Master Fund (the "GP"), and (iii) Eli Casdin, the managing member of Casdin and the GP.
F3: Represents a cross-trade, pursuant to which Casdin FO1 transferred 545,000 shares of Common Stock to Casdin Amplify Fund, LP ("Amplify").
F4: The securities are owned directly by Amplify and are deemed to be indirectly beneficially owned by (i) Casdin, the investment adviser to Amplify, (ii) the GP, the general partner of Amplify, and (iii) Eli Casdin, the managing member of Casdin Capital, LLC and Casdin Partners GP, LLC.
F5: Represents a cross-trade, pursuant to which Casdin FO1 transferred 1,200,000 shares of Common Stock to the Master Fund and Amplify.
F6: The securities were owned directly by Casdin FO1 and were deemed to be indirectly beneficially owned by (i) Casdin, the investment adviser to Casdin FO1, (ii) the GP, the general partner of Casdin FO1, and (iii) Eli Casdin, the managing member of Casdin Capital, LLC and Casdin Partners GP, LLC.
F7: The securities are owned directly by Casdin Private Growth Equity Fund II, L.P. (the "Equity Fund II") and may be deemed to be indirectly beneficially owned by (i) Casdin, the investment adviser to the Equity Fund II, and (ii) Eli Casdin, the managing member of Casdin.
F8: The securities are owned directly by Eli Casdin.
F9: The securities are owned directly by Casdin Private Growth Equity Fund, L.P. (the "Equity Fund") and may be deemed to be indirectly beneficially owned by (i) Casdin, the investment adviser to the Equity Fund, and (ii) Eli Casdin, the managing member of Casdin.
F10: The securities are indirectly owned by Eli Casdin who has voting and investment discretion with respect to the securities.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| June 18, 2024 Filed Jun 22, 2024 00:53 UTC | STANDARD BIOTOOLS INC. LAB · Entity 6116 | OtherCommon Stock | 1,200,000 | $2.05 | $2,460,000.00 |
DisclosureSEC source: 0000919574-24-003795 · ownership.xml · nonDerivative · entry 3 Casdin Partners Master Fund, L.P. · CIK 0001534265 · Director · 10% owner Casdin Capital, LLC · CIK 0001534261 · Director · 10% owner Casdin Partners GP, LLC · CIK 0001534260 · Director · 10% owner Casdin Private Growth Equity Fund II, L.P. · CIK 0001891102 · Director Casdin Private Growth Equity Fund II GP, LLC · CIK 0001919480 · Director Casdin Partners FO1-MSV, LP · CIK 0001938709 · Director Casdin Private Growth Equity Fund, L.P. · CIK 0001823061 · Director CASDIN PRIVATE GROWTH EQUITY FUND GP, LLC · CIK 0001864554 · Director Casdin Eli · CIK 0001534264 · Director · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · See footnote. Disclosed balance after: 0 F5 · kind: Represents a cross-trade, pursuant to which Casdin FO1 transferred 1,200,000 shares of Common Stock to the Master Fund and Amplify. F6 · ownership.nature: The securities were owned directly by Casdin FO1 and were deemed to be indirectly beneficially owned by (i) Casdin, the investment adviser to Casdin FO1, (ii) the GP, the general partner of Casdin FO1, and (iii) Eli Casdin, the managing member of Casdin Capital, LLC and Casdin Partners GP, LLC. Read SEC document |
| June 18, 2024 Filed Jun 22, 2024 00:53 UTC | STANDARD BIOTOOLS INC. LAB · Entity 6116 | OtherCommon Stock | 545,000 | $2.05 | $1,117,250.00 |
DisclosureSEC source: 0000919574-24-003795 · ownership.xml · nonDerivative · entry 2 Casdin Partners Master Fund, L.P. · CIK 0001534265 · Director · 10% owner Casdin Capital, LLC · CIK 0001534261 · Director · 10% owner Casdin Partners GP, LLC · CIK 0001534260 · Director · 10% owner Casdin Private Growth Equity Fund II, L.P. · CIK 0001891102 · Director Casdin Private Growth Equity Fund II GP, LLC · CIK 0001919480 · Director Casdin Partners FO1-MSV, LP · CIK 0001938709 · Director Casdin Private Growth Equity Fund, L.P. · CIK 0001823061 · Director CASDIN PRIVATE GROWTH EQUITY FUND GP, LLC · CIK 0001864554 · Director Casdin Eli · CIK 0001534264 · Director · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · See footnote. Disclosed balance after: 545,000 F3 · kind: Represents a cross-trade, pursuant to which Casdin FO1 transferred 545,000 shares of Common Stock to Casdin Amplify Fund, LP ("Amplify"). F4 · ownership.nature: The securities are owned directly by Amplify and are deemed to be indirectly beneficially owned by (i) Casdin, the investment adviser to Amplify, (ii) the GP, the general partner of Amplify, and (iii) Eli Casdin, the managing member of Casdin Capital, LLC and Casdin Partners GP, LLC. Read SEC document |
| June 18, 2024 Filed Jun 22, 2024 00:53 UTC | STANDARD BIOTOOLS INC. LAB · Entity 6116 | OtherCommon Stock | 655,000 | $2.05 | $1,342,750.00 |
DisclosureSEC source: 0000919574-24-003795 · ownership.xml · nonDerivative · entry 1 Casdin Partners Master Fund, L.P. · CIK 0001534265 · Director · 10% owner Casdin Capital, LLC · CIK 0001534261 · Director · 10% owner Casdin Partners GP, LLC · CIK 0001534260 · Director · 10% owner Casdin Private Growth Equity Fund II, L.P. · CIK 0001891102 · Director Casdin Private Growth Equity Fund II GP, LLC · CIK 0001919480 · Director Casdin Partners FO1-MSV, LP · CIK 0001938709 · Director Casdin Private Growth Equity Fund, L.P. · CIK 0001823061 · Director CASDIN PRIVATE GROWTH EQUITY FUND GP, LLC · CIK 0001864554 · Director Casdin Eli · CIK 0001534264 · Director · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · See footnote. Disclosed balance after: 46,730,821 F1 · kind: Represents a cross-trade, pursuant to which Casdin Partners FO1-MSV, LP ("Casdin FO1") transferred 655,000 shares of Common Stock to Casdin Partners Master Fund, L.P. (the "Master Fund"). F2 · ownership.nature: The securities are owned directly by the Master Fund and may be deemed to be indirectly beneficially owned by (i) Casdin Capital, LLC, the investment adviser to the Master Fund ("Casdin"), (ii) Casdin Partners GP, LLC, the general partner of the Master Fund (the "GP"), and (iii) Eli Casdin, the managing member of Casdin and the GP. Read SEC document |
| June 04, 2024 Filed Jun 5, 2024 20:45 UTC | GeneDx Holdings Corp. WGS · Entity 1634 | PurchaseClass A Common Stock | 30,000 | $22.52 | $675,477.00 |
DisclosureSEC source: 0000919574-24-003510 · ownership.xml · nonDerivative · entry 2 Casdin Capital, LLC · CIK 0001534261 · Director · 10% owner Casdin Eli · CIK 0001534264 · Director · 10% owner Casdin Partners Master Fund, L.P. · CIK 0001534265 · Director · 10% owner Casdin Partners GP, LLC · CIK 0001534260 · Director · 10% owner Casdin Partners FO1-MSV, LP · CIK 0001938709 · Director Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 3,093,509 F3 · price: The price reported in Column 4 is a weighted average price. These shares were bought in multiple transactions within the range of $21.8623 to $22.8427. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares bought at each separate price within the range set forth in this footnote. F2 · ownership.direct: The securities are owned directly by Casdin Partners Master Fund, L.P. (the "Master Fund") and may be deemed to be indirectly beneficially owned by (i) Casdin Capital, LLC, the investment adviser to the Master Fund ("Casdin"), (ii) Casdin Partners GP, LLC, the general partner of the Master Fund (the "GP"), and (iii) Eli Casdin, the managing member of Casdin and the GP. Read SEC document |
| June 03, 2024 Filed Jun 5, 2024 20:45 UTC | GeneDx Holdings Corp. WGS · Entity 1634 | PurchaseClass A Common Stock | 100,000 | $20.82 | $2,081,640.00 |
DisclosureSEC source: 0000919574-24-003510 · ownership.xml · nonDerivative · entry 1 Casdin Capital, LLC · CIK 0001534261 · Director · 10% owner Casdin Eli · CIK 0001534264 · Director · 10% owner Casdin Partners Master Fund, L.P. · CIK 0001534265 · Director · 10% owner Casdin Partners GP, LLC · CIK 0001534260 · Director · 10% owner Casdin Partners FO1-MSV, LP · CIK 0001938709 · Director Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 3,063,509 F1 · price: The price reported in Column 4 is a weighted average price. These shares were bought in multiple transactions within the range of $20.6824 to $20.9659. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares bought at each separate price within the range set forth in this footnote. F2 · ownership.direct: The securities are owned directly by Casdin Partners Master Fund, L.P. (the "Master Fund") and may be deemed to be indirectly beneficially owned by (i) Casdin Capital, LLC, the investment adviser to the Master Fund ("Casdin"), (ii) Casdin Partners GP, LLC, the general partner of the Master Fund (the "GP"), and (iii) Eli Casdin, the managing member of Casdin and the GP. Read SEC document |
| May 29, 2024 Filed May 31, 2024 17:37 UTC | GeneDx Holdings Corp. WGS · Entity 1634 | PurchaseClass A Common Stock | 40,000 | $21.07 | $842,604.00 |
DisclosureSEC source: 0000919574-24-003432 · ownership.xml · nonDerivative · entry 1 Casdin Capital, LLC · CIK 0001534261 · Director · 10% owner Casdin Eli · CIK 0001534264 · Director · 10% owner Casdin Partners Master Fund, L.P. · CIK 0001534265 · Director · 10% owner Casdin Partners GP, LLC · CIK 0001534260 · Director · 10% owner Casdin Partners FO1-MSV, LP · CIK 0001938709 · Director Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,963,509 F1 · price: The price reported in Column 4 is a weighted average price. These shares were bought in multiple transactions within the range of $20.9752 to $21.1876. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares bought at each separate price within the range set forth in this footnote. F2 · ownership.direct: The securities are owned directly by Casdin Partners Master Fund, L.P. (the "Master Fund") and may be deemed to be indirectly beneficially owned by (i) Casdin Capital, LLC, the investment adviser to the Master Fund ("Casdin"), (ii) Casdin Partners GP, LLC, the general partner of the Master Fund (the "GP"), and (iii) Eli Casdin, the managing member of Casdin and the GP. Read SEC document |
| May 28, 2024 Filed May 28, 2024 20:40 UTC | GeneDx Holdings Corp. WGS · Entity 1634 | PurchaseClass A Common Stock | 18,304 | $20.61 | $377,166.73 |
DisclosureSEC source: 0000919574-24-003355 · ownership.xml · nonDerivative · entry 3 Casdin Capital, LLC · CIK 0001534261 · Director · 10% owner Casdin Eli · CIK 0001534264 · Director · 10% owner Casdin Partners Master Fund, L.P. · CIK 0001534265 · Director · 10% owner Casdin Partners GP, LLC · CIK 0001534260 · Director · 10% owner Casdin Partners FO1-MSV, LP · CIK 0001938709 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,923,509 F2 · ownership.direct: The securities are owned directly by Casdin Partners Master Fund, L.P. (the "Master Fund") and may be deemed to be indirectly beneficially owned by (i) Casdin Capital, LLC, the investment adviser to the Master Fund ("Casdin"), (ii) Casdin Partners GP, LLC, the general partner of the Master Fund (the "GP"), and (iii) Eli Casdin, the managing member of Casdin and the GP. Read SEC document |
| May 24, 2024 Filed May 28, 2024 20:40 UTC | GeneDx Holdings Corp. WGS · Entity 1634 | PurchaseClass A Common Stock | 144,196 | $20.12 | $2,900,906.29 |
DisclosureSEC source: 0000919574-24-003355 · ownership.xml · nonDerivative · entry 2 Casdin Capital, LLC · CIK 0001534261 · Director · 10% owner Casdin Eli · CIK 0001534264 · Director · 10% owner Casdin Partners Master Fund, L.P. · CIK 0001534265 · Director · 10% owner Casdin Partners GP, LLC · CIK 0001534260 · Director · 10% owner Casdin Partners FO1-MSV, LP · CIK 0001938709 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,905,205 F3 · price: The price reported in Column 4 is a weighted average price. These shares were bought in multiple transactions within the range of $20 to $20.55. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares bought at each separate price within the range set forth in this footnote. F2 · ownership.direct: The securities are owned directly by Casdin Partners Master Fund, L.P. (the "Master Fund") and may be deemed to be indirectly beneficially owned by (i) Casdin Capital, LLC, the investment adviser to the Master Fund ("Casdin"), (ii) Casdin Partners GP, LLC, the general partner of the Master Fund (the "GP"), and (iii) Eli Casdin, the managing member of Casdin and the GP. Read SEC document |
| May 23, 2024 Filed May 29, 2024 00:45 UTC | STANDARD BIOTOOLS INC. LAB · Entity 6116 | PurchaseCommon Stock | 100,000 | $2.60 | $260,000.00 |
DisclosureSEC source: 0000919574-24-003356 · ownership.xml · nonDerivative · entry 1 Casdin Partners Master Fund, L.P. · CIK 0001534265 · Director · 10% owner Casdin Eli · CIK 0001534264 · Director · 10% owner Casdin Capital, LLC · CIK 0001534261 · Director · 10% owner Casdin Partners GP, LLC · CIK 0001534260 · Director · 10% owner Casdin Private Growth Equity Fund II, L.P. · CIK 0001891102 · Director Casdin Private Growth Equity Fund II GP, LLC · CIK 0001919480 · Director Casdin Private Growth Equity Fund, L.P. · CIK 0001823061 · Director CASDIN PRIVATE GROWTH EQUITY FUND GP, LLC · CIK 0001864554 · Director Casdin Partners FO1-MSV, LP · CIK 0001938709 · Director Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · See footnote Disclosed balance after: 46,075,821 F1 · ownership.nature: The securities are owned directly by Casdin Partners Master Fund, L.P. (the "Master Fund") and may be deemed to be indirectly beneficially owned by (i) Casdin Capital, LLC, the investment adviser to the Master Fund ("Casdin"), (ii) Casdin Partners GP, LLC, the general partner of the Master Fund (the "GP"), and (iii) Eli Casdin, the managing member of Casdin and the GP. Read SEC document |
| May 23, 2024 Filed May 28, 2024 20:40 UTC | GeneDx Holdings Corp. WGS · Entity 1634 | PurchaseClass A Common Stock | 7,500 | $19.59 | $146,916.00 |
DisclosureSEC source: 0000919574-24-003355 · ownership.xml · nonDerivative · entry 1 Casdin Capital, LLC · CIK 0001534261 · Director · 10% owner Casdin Eli · CIK 0001534264 · Director · 10% owner Casdin Partners Master Fund, L.P. · CIK 0001534265 · Director · 10% owner Casdin Partners GP, LLC · CIK 0001534260 · Director · 10% owner Casdin Partners FO1-MSV, LP · CIK 0001938709 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,761,009 F1 · price: The price reported in Column 4 is a weighted average price. These shares were bought in multiple transactions within the range of $19.5662 to $19.6341. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares bought at each separate price within the range set forth in this footnote. F2 · ownership.direct: The securities are owned directly by Casdin Partners Master Fund, L.P. (the "Master Fund") and may be deemed to be indirectly beneficially owned by (i) Casdin Capital, LLC, the investment adviser to the Master Fund ("Casdin"), (ii) Casdin Partners GP, LLC, the general partner of the Master Fund (the "GP"), and (iii) Eli Casdin, the managing member of Casdin and the GP. Read SEC document |
| May 22, 2024 Filed May 22, 2024 23:53 UTC | STANDARD BIOTOOLS INC. LAB · Entity 6116 | PurchaseCommon Stock | 150,000 | $2.58 | $387,735.00 |
DisclosureSEC source: 0000919574-24-003308 · ownership.xml · nonDerivative · entry 3 Casdin Partners Master Fund, L.P. · CIK 0001534265 · Director · 10% owner Casdin Eli · CIK 0001534264 · Director · 10% owner Casdin Capital, LLC · CIK 0001534261 · Director · 10% owner Casdin Partners GP, LLC · CIK 0001534260 · Director · 10% owner Casdin Private Growth Equity Fund II, L.P. · CIK 0001891102 · Director Casdin Private Growth Equity Fund II GP, LLC · CIK 0001919480 · Director Casdin Private Growth Equity Fund, L.P. · CIK 0001823061 · Director CASDIN PRIVATE GROWTH EQUITY FUND GP, LLC · CIK 0001864554 · Director Casdin Partners FO1-MSV, LP · CIK 0001938709 · Director Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · See footnote Disclosed balance after: 45,975,821 F4 · price: The price reported in Column 4 is a weighted average price. These shares were bought in multiple transactions within the range of $2.5771 to $2.5865. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares bought at each separate price within the range set forth in this footnote. F2 · ownership.nature: The securities are owned directly by Casdin Partners Master Fund, L.P. (the "Master Fund") and may be deemed to be indirectly beneficially owned by (i) Casdin Capital, LLC, the investment adviser to the Master Fund ("Casdin"), (ii) Casdin Partners GP, LLC, the general partner of the Master Fund (the "GP"), and (iii) Eli Casdin, the managing member of Casdin and the GP. Read SEC document |
| May 21, 2024 Filed May 22, 2024 23:53 UTC | STANDARD BIOTOOLS INC. LAB · Entity 6116 | PurchaseCommon Stock | 350,000 | $2.56 | $895,930.00 |
DisclosureSEC source: 0000919574-24-003308 · ownership.xml · nonDerivative · entry 2 Casdin Partners Master Fund, L.P. · CIK 0001534265 · Director · 10% owner Casdin Eli · CIK 0001534264 · Director · 10% owner Casdin Capital, LLC · CIK 0001534261 · Director · 10% owner Casdin Partners GP, LLC · CIK 0001534260 · Director · 10% owner Casdin Private Growth Equity Fund II, L.P. · CIK 0001891102 · Director Casdin Private Growth Equity Fund II GP, LLC · CIK 0001919480 · Director Casdin Private Growth Equity Fund, L.P. · CIK 0001823061 · Director CASDIN PRIVATE GROWTH EQUITY FUND GP, LLC · CIK 0001864554 · Director Casdin Partners FO1-MSV, LP · CIK 0001938709 · Director Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · See footnote Disclosed balance after: 45,825,821 F3 · price: The price reported in Column 4 is a weighted average price. These shares were bought in multiple transactions within the range of $2.5597 to $2.56. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares bought at each separate price within the range set forth in this footnote. F2 · ownership.nature: The securities are owned directly by Casdin Partners Master Fund, L.P. (the "Master Fund") and may be deemed to be indirectly beneficially owned by (i) Casdin Capital, LLC, the investment adviser to the Master Fund ("Casdin"), (ii) Casdin Partners GP, LLC, the general partner of the Master Fund (the "GP"), and (iii) Eli Casdin, the managing member of Casdin and the GP. Read SEC document |
| May 20, 2024 Filed May 22, 2024 23:53 UTC | STANDARD BIOTOOLS INC. LAB · Entity 6116 | PurchaseCommon Stock | 100,000 | $2.58 | $258,130.00 |
DisclosureSEC source: 0000919574-24-003308 · ownership.xml · nonDerivative · entry 1 Casdin Partners Master Fund, L.P. · CIK 0001534265 · Director · 10% owner Casdin Eli · CIK 0001534264 · Director · 10% owner Casdin Capital, LLC · CIK 0001534261 · Director · 10% owner Casdin Partners GP, LLC · CIK 0001534260 · Director · 10% owner Casdin Private Growth Equity Fund II, L.P. · CIK 0001891102 · Director Casdin Private Growth Equity Fund II GP, LLC · CIK 0001919480 · Director Casdin Private Growth Equity Fund, L.P. · CIK 0001823061 · Director CASDIN PRIVATE GROWTH EQUITY FUND GP, LLC · CIK 0001864554 · Director Casdin Partners FO1-MSV, LP · CIK 0001938709 · Director Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · See footnote Disclosed balance after: 45,475,821 F1 · price: The price reported in Column 4 is a weighted average price. These shares were bought in multiple transactions within the range of $2.5791 to $2.5858. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares bought at each separate price within the range set forth in this footnote. F2 · ownership.nature: The securities are owned directly by Casdin Partners Master Fund, L.P. (the "Master Fund") and may be deemed to be indirectly beneficially owned by (i) Casdin Capital, LLC, the investment adviser to the Master Fund ("Casdin"), (ii) Casdin Partners GP, LLC, the general partner of the Master Fund (the "GP"), and (iii) Eli Casdin, the managing member of Casdin and the GP. Read SEC document |
| May 17, 2024 Filed May 18, 2024 00:11 UTC | STANDARD BIOTOOLS INC. LAB · Entity 6116 | PurchaseCommon Stock | 352,072 | $2.56 | $902,043.67 |
DisclosureSEC source: 0000919574-24-003252 · ownership.xml · nonDerivative · entry 3 Casdin Partners Master Fund, L.P. · CIK 0001534265 · Director · 10% owner Casdin Eli · CIK 0001534264 · Director · 10% owner Casdin Capital, LLC · CIK 0001534261 · Director · 10% owner Casdin Partners GP, LLC · CIK 0001534260 · Director · 10% owner Casdin Private Growth Equity Fund II, L.P. · CIK 0001891102 · Director Casdin Private Growth Equity Fund II GP, LLC · CIK 0001919480 · Director Casdin Private Growth Equity Fund, L.P. · CIK 0001823061 · Director CASDIN PRIVATE GROWTH EQUITY FUND GP, LLC · CIK 0001864554 · Director Casdin Partners FO1-MSV, LP · CIK 0001938709 · Director Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · See footnote. Disclosed balance after: 45,375,821 F4 · price: The price reported in Column 4 is a weighted average price. These shares were bought in multiple transactions within the range of $2.5381 to $2.5798. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares bought at each separate price within the range set forth in this footnote. F2 · ownership.nature: The securities are owned directly by Casdin Partners Master Fund, L.P. (the "Master Fund") and may be deemed to be indirectly beneficially owned by (i) Casdin Capital, LLC, the investment adviser to the Master Fund ("Casdin"), (ii) Casdin Partners GP, LLC, the general partner of the Master Fund (the "GP"), and (iii) Eli Casdin, the managing member of Casdin and the GP. Read SEC document |
| May 16, 2024 Filed May 18, 2024 00:11 UTC | STANDARD BIOTOOLS INC. LAB · Entity 6116 | PurchaseCommon Stock | 500,000 | $2.54 | $1,270,950.00 |
DisclosureSEC source: 0000919574-24-003252 · ownership.xml · nonDerivative · entry 2 Casdin Partners Master Fund, L.P. · CIK 0001534265 · Director · 10% owner Casdin Eli · CIK 0001534264 · Director · 10% owner Casdin Capital, LLC · CIK 0001534261 · Director · 10% owner Casdin Partners GP, LLC · CIK 0001534260 · Director · 10% owner Casdin Private Growth Equity Fund II, L.P. · CIK 0001891102 · Director Casdin Private Growth Equity Fund II GP, LLC · CIK 0001919480 · Director Casdin Private Growth Equity Fund, L.P. · CIK 0001823061 · Director CASDIN PRIVATE GROWTH EQUITY FUND GP, LLC · CIK 0001864554 · Director Casdin Partners FO1-MSV, LP · CIK 0001938709 · Director Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · See footnote. Disclosed balance after: 45,023,749 F3 · price: The price reported in Column 4 is a weighted average price. These shares were bought in multiple transactions within the range of $2.5381 to $2.5429. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares bought at each separate price within the range set forth in this footnote. F2 · ownership.nature: The securities are owned directly by Casdin Partners Master Fund, L.P. (the "Master Fund") and may be deemed to be indirectly beneficially owned by (i) Casdin Capital, LLC, the investment adviser to the Master Fund ("Casdin"), (ii) Casdin Partners GP, LLC, the general partner of the Master Fund (the "GP"), and (iii) Eli Casdin, the managing member of Casdin and the GP. Read SEC document |
| May 15, 2024 Filed May 18, 2024 00:11 UTC | STANDARD BIOTOOLS INC. LAB · Entity 6116 | PurchaseCommon Stock | 500,000 | $2.57 | $1,282,550.00 |
DisclosureSEC source: 0000919574-24-003252 · ownership.xml · nonDerivative · entry 1 Casdin Partners Master Fund, L.P. · CIK 0001534265 · Director · 10% owner Casdin Eli · CIK 0001534264 · Director · 10% owner Casdin Capital, LLC · CIK 0001534261 · Director · 10% owner Casdin Partners GP, LLC · CIK 0001534260 · Director · 10% owner Casdin Private Growth Equity Fund II, L.P. · CIK 0001891102 · Director Casdin Private Growth Equity Fund II GP, LLC · CIK 0001919480 · Director Casdin Private Growth Equity Fund, L.P. · CIK 0001823061 · Director CASDIN PRIVATE GROWTH EQUITY FUND GP, LLC · CIK 0001864554 · Director Casdin Partners FO1-MSV, LP · CIK 0001938709 · Director Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · See footnote. Disclosed balance after: 44,523,749 F1 · price: The price reported in Column 4 is a weighted average price. These shares were bought in multiple transactions within the range of $2.5473 to $2.58. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares bought at each separate price within the range set forth in this footnote. F2 · ownership.nature: The securities are owned directly by Casdin Partners Master Fund, L.P. (the "Master Fund") and may be deemed to be indirectly beneficially owned by (i) Casdin Capital, LLC, the investment adviser to the Master Fund ("Casdin"), (ii) Casdin Partners GP, LLC, the general partner of the Master Fund (the "GP"), and (iii) Eli Casdin, the managing member of Casdin and the GP. Read SEC document |
| May 13, 2024 Filed May 15, 2024 18:16 UTC | GeneDx Holdings Corp. WGS · Entity 1634 | PurchaseClass A Common Stock | 50,000 | $23.31 | $1,165,295.00 |
DisclosureSEC source: 0000919574-24-003212 · ownership.xml · nonDerivative · entry 1 Casdin Capital, LLC · CIK 0001534261 · Director · 10% owner Casdin Eli · CIK 0001534264 · Director · 10% owner Casdin Partners Master Fund, L.P. · CIK 0001534265 · Director · 10% owner Casdin Partners GP, LLC · CIK 0001534260 · Director · 10% owner Casdin Partners FO1-MSV, LP · CIK 0001938709 · Director · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,753,509 F1 · ownership.direct: The securities are owned directly by Casdin Partners Master Fund, L.P. (the "Master Fund") and may be deemed to be indirectly beneficially owned by (i) Casdin Capital, LLC, the investment adviser to the Master Fund ("Casdin"), (ii) Casdin Partners GP, LLC, the general partner of the Master Fund (the "GP"), and (iii) Eli Casdin, the managing member of Casdin and the GP. Read SEC document |
| March 18, 2024 Filed Mar 20, 2024 21:54 UTC | STANDARD BIOTOOLS INC. LAB · Entity 6116 | Disposition to issuerSeries B-1 Convertible Preferred Stock · Derivative | 38,334 | $2.75 Strike: $2.75 | $105,418.50 |
DisclosureSEC source: 0000919574-24-002115 · ownership.xml · derivative · entry 8 Casdin Partners Master Fund, L.P. · CIK 0001534265 · Director · 10% owner Casdin Capital, LLC · CIK 0001534261 · Director · 10% owner Casdin Partners GP, LLC · CIK 0001534260 · Director · 10% owner Casdin Private Growth Equity Fund II, L.P. · CIK 0001891102 · Director Casdin Private Growth Equity Fund II GP, LLC · CIK 0001919480 · Director Casdin Partners FO1-MSV, LP · CIK 0001938709 · Director Casdin Private Growth Equity Fund, L.P. · CIK 0001823061 · Director CASDIN PRIVATE GROWTH EQUITY FUND GP, LLC · CIK 0001864554 · Director Casdin Eli · CIK 0001534264 · Director · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · See footnote Disclosed balance after: 0 Underlying: Common Stock · 13,939,637 shares Expires not disclosed F7 · derivative.exercise_date: Each share of the Issuer's Series B-1 Convertible Preferred Stock (the "Series B-1 Preferred Stock") was convertible at the option of the Reporting Person at any time into a number of shares of the Issuer's common stock, par value $0.001 per share. F7 · derivative.expiration_date: Each share of the Issuer's Series B-1 Convertible Preferred Stock (the "Series B-1 Preferred Stock") was convertible at the option of the Reporting Person at any time into a number of shares of the Issuer's common stock, par value $0.001 per share. F2 · ownership.nature: The securities are owned directly by Casdin Private Growth Equity Fund II, L.P. (the "Equity Fund II") and may be deemed to be indirectly beneficially owned by (i) Casdin, the investment adviser to the Equity Fund II, and (ii) Eli Casdin, the managing member of Casdin. Read SEC document |
| March 18, 2024 Filed Mar 20, 2024 21:54 UTC | STANDARD BIOTOOLS INC. LAB · Entity 6116 | Disposition to issuerSeries B-1 Convertible Preferred Stock · Derivative | 89,446 | $2.75 Strike: $2.75 | $245,976.50 |
DisclosureSEC source: 0000919574-24-002115 · ownership.xml · derivative · entry 7 Casdin Partners Master Fund, L.P. · CIK 0001534265 · Director · 10% owner Casdin Capital, LLC · CIK 0001534261 · Director · 10% owner Casdin Partners GP, LLC · CIK 0001534260 · Director · 10% owner Casdin Private Growth Equity Fund II, L.P. · CIK 0001891102 · Director Casdin Private Growth Equity Fund II GP, LLC · CIK 0001919480 · Director Casdin Partners FO1-MSV, LP · CIK 0001938709 · Director Casdin Private Growth Equity Fund, L.P. · CIK 0001823061 · Director CASDIN PRIVATE GROWTH EQUITY FUND GP, LLC · CIK 0001864554 · Director Casdin Eli · CIK 0001534264 · Director · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · See footnote Disclosed balance after: 0 Underlying: Common Stock · 32,525,821 shares Expires not disclosed F7 · derivative.exercise_date: Each share of the Issuer's Series B-1 Convertible Preferred Stock (the "Series B-1 Preferred Stock") was convertible at the option of the Reporting Person at any time into a number of shares of the Issuer's common stock, par value $0.001 per share. F7 · derivative.expiration_date: Each share of the Issuer's Series B-1 Convertible Preferred Stock (the "Series B-1 Preferred Stock") was convertible at the option of the Reporting Person at any time into a number of shares of the Issuer's common stock, par value $0.001 per share. F1 · ownership.nature: The securities are owned directly by Casdin Partners Master Fund, L.P. (the "Master Fund") and may be deemed to be indirectly beneficially owned by (i) Casdin Capital, LLC, the investment adviser to the Master Fund ("Casdin"), (ii) Casdin Partners GP, LLC, the general partner of the Master Fund (the "GP"), and (iii) Eli Casdin, the managing member of Casdin and the GP. Read SEC document |
| March 18, 2024 Filed Mar 20, 2024 21:54 UTC | STANDARD BIOTOOLS INC. LAB · Entity 6116 | GrantCommon Stock | 13,939,637 | $2.75 | $38,334,001.75 |
DisclosureSEC source: 0000919574-24-002115 · ownership.xml · nonDerivative · entry 2 Casdin Partners Master Fund, L.P. · CIK 0001534265 · Director · 10% owner Casdin Capital, LLC · CIK 0001534261 · Director · 10% owner Casdin Partners GP, LLC · CIK 0001534260 · Director · 10% owner Casdin Private Growth Equity Fund II, L.P. · CIK 0001891102 · Director Casdin Private Growth Equity Fund II GP, LLC · CIK 0001919480 · Director Casdin Partners FO1-MSV, LP · CIK 0001938709 · Director Casdin Private Growth Equity Fund, L.P. · CIK 0001823061 · Director CASDIN PRIVATE GROWTH EQUITY FUND GP, LLC · CIK 0001864554 · Director Casdin Eli · CIK 0001534264 · Director · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · See footnote Disclosed balance after: 13,939,637 F2 · ownership.nature: The securities are owned directly by Casdin Private Growth Equity Fund II, L.P. (the "Equity Fund II") and may be deemed to be indirectly beneficially owned by (i) Casdin, the investment adviser to the Equity Fund II, and (ii) Eli Casdin, the managing member of Casdin. Read SEC document |
| March 18, 2024 Filed Mar 20, 2024 21:54 UTC | STANDARD BIOTOOLS INC. LAB · Entity 6116 | GrantCommon Stock | 32,525,821 | $2.75 | $89,446,007.75 |
DisclosureSEC source: 0000919574-24-002115 · ownership.xml · nonDerivative · entry 1 Casdin Partners Master Fund, L.P. · CIK 0001534265 · Director · 10% owner Casdin Capital, LLC · CIK 0001534261 · Director · 10% owner Casdin Partners GP, LLC · CIK 0001534260 · Director · 10% owner Casdin Private Growth Equity Fund II, L.P. · CIK 0001891102 · Director Casdin Private Growth Equity Fund II GP, LLC · CIK 0001919480 · Director Casdin Partners FO1-MSV, LP · CIK 0001938709 · Director Casdin Private Growth Equity Fund, L.P. · CIK 0001823061 · Director CASDIN PRIVATE GROWTH EQUITY FUND GP, LLC · CIK 0001864554 · Director Casdin Eli · CIK 0001534264 · Director · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · See footnote Disclosed balance after: 44,023,749 F1 · ownership.nature: The securities are owned directly by Casdin Partners Master Fund, L.P. (the "Master Fund") and may be deemed to be indirectly beneficially owned by (i) Casdin Capital, LLC, the investment adviser to the Master Fund ("Casdin"), (ii) Casdin Partners GP, LLC, the general partner of the Master Fund (the "GP"), and (iii) Eli Casdin, the managing member of Casdin and the GP. Read SEC document |
| March 05, 2024 Filed Mar 7, 2024 00:20 UTC | STANDARD BIOTOOLS INC. LAB · Entity 6116 | PurchaseCommon Stock | 1,403 | $2.62 | $3,668.85 |
DisclosureSEC source: 0000919574-24-001888 · ownership.xml · nonDerivative · entry 2 Casdin Partners Master Fund, L.P. · CIK 0001534265 · Director · 10% owner Casdin Capital, LLC · CIK 0001534261 · Director · 10% owner Casdin Partners GP, LLC · CIK 0001534260 · Director · 10% owner Casdin Private Growth Equity Fund II, L.P. · CIK 0001891102 · Director Casdin Private Growth Equity Fund II GP, LLC · CIK 0001919480 · Director Casdin Partners FO1-MSV, LP · CIK 0001938709 · Director Casdin Private Growth Equity Fund, L.P. · CIK 0001823061 · Director CASDIN PRIVATE GROWTH EQUITY FUND GP, LLC · CIK 0001864554 · Director Casdin Eli · CIK 0001534264 · Director · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 11,497,928 F2 · ownership.direct: The securities are owned directly by Casdin Partners Master Fund, L.P. (the "Master Fund") and may be deemed to be indirectly beneficially owned by (i) Casdin Capital, LLC, the investment adviser to the Master Fund ("Casdin"), (ii) Casdin Partners GP, LLC, the general partner of the Master Fund (the "GP"), and (iii) Eli Casdin, the managing member of Casdin and the GP. Read SEC document |
| March 05, 2024 Filed Mar 6, 2024 19:32 UTC | GeneDx Holdings Corp. WGS · Entity 1634 | PurchaseClass A Common Stock | 900 | $8.83 | $7,944.30 |
DisclosureSEC source: 0000919574-24-001889 · ownership.xml · nonDerivative · entry 2 Casdin Capital, LLC · CIK 0001534261 · Director · 10% owner Casdin Eli · CIK 0001534264 · Director · 10% owner Casdin Partners Master Fund, L.P. · CIK 0001534265 · Director · 10% owner Casdin Partners GP, LLC · CIK 0001534260 · Director · 10% owner Casdin Partners FO1-MSV, LP · CIK 0001938709 · Director Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,703,509 F3 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions within the range of $8.8236 to $8.84. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote. F2 · ownership.direct: The securities are owned directly by Casdin Partners Master Fund, L.P. (the "Master Fund") and may be deemed to be indirectly beneficially owned by (i) Casdin Capital, LLC, the investment adviser to the Master Fund ("Casdin"), (ii) Casdin Partners GP, LLC, the general partner of the Master Fund (the "GP"), and (iii) Eli Casdin, the managing member of Casdin and the GP. Read SEC document |
| March 04, 2024 Filed Mar 7, 2024 00:20 UTC | STANDARD BIOTOOLS INC. LAB · Entity 6116 | PurchaseCommon Stock | 250,000 | $2.57 | $642,500.00 |
DisclosureSEC source: 0000919574-24-001888 · ownership.xml · nonDerivative · entry 1 Casdin Partners Master Fund, L.P. · CIK 0001534265 · Director · 10% owner Casdin Capital, LLC · CIK 0001534261 · Director · 10% owner Casdin Partners GP, LLC · CIK 0001534260 · Director · 10% owner Casdin Private Growth Equity Fund II, L.P. · CIK 0001891102 · Director Casdin Private Growth Equity Fund II GP, LLC · CIK 0001919480 · Director Casdin Partners FO1-MSV, LP · CIK 0001938709 · Director Casdin Private Growth Equity Fund, L.P. · CIK 0001823061 · Director CASDIN PRIVATE GROWTH EQUITY FUND GP, LLC · CIK 0001864554 · Director Casdin Eli · CIK 0001534264 · Director · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 11,496,525 F1 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions within the range of $2.5525 to $2.616. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote. F2 · ownership.direct: The securities are owned directly by Casdin Partners Master Fund, L.P. (the "Master Fund") and may be deemed to be indirectly beneficially owned by (i) Casdin Capital, LLC, the investment adviser to the Master Fund ("Casdin"), (ii) Casdin Partners GP, LLC, the general partner of the Master Fund (the "GP"), and (iii) Eli Casdin, the managing member of Casdin and the GP. Read SEC document |
| March 04, 2024 Filed Mar 6, 2024 19:32 UTC | GeneDx Holdings Corp. WGS · Entity 1634 | PurchaseClass A Common Stock | 40,000 | $8.74 | $349,708.00 |
DisclosureSEC source: 0000919574-24-001889 · ownership.xml · nonDerivative · entry 1 Casdin Capital, LLC · CIK 0001534261 · Director · 10% owner Casdin Eli · CIK 0001534264 · Director · 10% owner Casdin Partners Master Fund, L.P. · CIK 0001534265 · Director · 10% owner Casdin Partners GP, LLC · CIK 0001534260 · Director · 10% owner Casdin Partners FO1-MSV, LP · CIK 0001938709 · Director Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,702,609 F1 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions within the range of $8.6895 to $8.7811. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote. F2 · ownership.direct: The securities are owned directly by Casdin Partners Master Fund, L.P. (the "Master Fund") and may be deemed to be indirectly beneficially owned by (i) Casdin Capital, LLC, the investment adviser to the Master Fund ("Casdin"), (ii) Casdin Partners GP, LLC, the general partner of the Master Fund (the "GP"), and (iii) Eli Casdin, the managing member of Casdin and the GP. Read SEC document |
| January 05, 2024 Filed Jan 10, 2024 01:51 UTC | STANDARD BIOTOOLS INC. LAB · Entity 6116 | GrantCommon Stock | 2,744,219 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000919574-24-000224 · ownership.xml · nonDerivative · entry 2 Casdin Partners Master Fund, L.P. · CIK 0001534265 · Director · 10% owner Casdin Capital, LLC · CIK 0001534261 · Director · 10% owner Casdin Partners GP, LLC · CIK 0001534260 · Director · 10% owner Casdin Private Growth Equity Fund II, L.P. · CIK 0001891102 · Director Casdin Private Growth Equity Fund II GP, LLC · CIK 0001919480 · Director Casdin Private Growth Equity Fund, L.P. · CIK 0001823061 · Director CASDIN PRIVATE GROWTH EQUITY FUND GP, LLC · CIK 0001864554 · Director Casdin Partners FO1-MSV, LP · CIK 0001938709 · Director Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · See footnote Disclosed balance after: 2,744,219 F2 · price: Received in exchange for 2,472,270 shares of common stock of SomaLogic pursuant to the Merger. Per the terms of the Merger, each share of SomaLogic common stock was converted pursuant to the Exchange Ratio at the Effective Time. The securities are owned directly by Casdin Private Growth Equity Fund, L.P. (the "Equity Fund") and may be deemed to be indirectly beneficially owned by (i) Casdin, the investment adviser to the Equity Fund, and (ii) Eli Casdin, the managing member of Casdin. F2 · ownership.nature: Received in exchange for 2,472,270 shares of common stock of SomaLogic pursuant to the Merger. Per the terms of the Merger, each share of SomaLogic common stock was converted pursuant to the Exchange Ratio at the Effective Time. The securities are owned directly by Casdin Private Growth Equity Fund, L.P. (the "Equity Fund") and may be deemed to be indirectly beneficially owned by (i) Casdin, the investment adviser to the Equity Fund, and (ii) Eli Casdin, the managing member of Casdin. Read SEC document |
| January 05, 2024 Filed Jan 10, 2024 01:51 UTC | STANDARD BIOTOOLS INC. LAB · Entity 6116 | GrantCommon Stock | 11,246,525 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000919574-24-000224 · ownership.xml · nonDerivative · entry 1 Casdin Partners Master Fund, L.P. · CIK 0001534265 · Director · 10% owner Casdin Capital, LLC · CIK 0001534261 · Director · 10% owner Casdin Partners GP, LLC · CIK 0001534260 · Director · 10% owner Casdin Private Growth Equity Fund II, L.P. · CIK 0001891102 · Director Casdin Private Growth Equity Fund II GP, LLC · CIK 0001919480 · Director Casdin Private Growth Equity Fund, L.P. · CIK 0001823061 · Director CASDIN PRIVATE GROWTH EQUITY FUND GP, LLC · CIK 0001864554 · Director Casdin Partners FO1-MSV, LP · CIK 0001938709 · Director Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 11,246,525 F1 · price: Received in exchange for 10,132,005 shares of common stock of SomaLogic, Inc. ("SomaLogic") pursuant to the Agreement and Plan of Merger (the "Merger Agreement"), dated October 4, 2023, by and among Standard BioTools Inc. (the "Company"), Martis Merger Sub, Inc. and SomaLogic (the "Merger"). Per the terms of the Merger, each share of SomaLogic common stock was converted into the right to receive 1.11 shares of the Company's common stock (the "Exchange Ratio") at the effective time of the Merger (the "Effective Time"). The securities are owned directly by Casdin Partners Master Fund, L.P. (the "Master Fund") and may be deemed to be indirectly beneficially owned by (i) Casdin Capital, LLC, the investment adviser to the Master Fund ("Casdin"), (ii) Casdin Partners GP, LLC, the general partner of the Master Fund (the "GP"), and (iii) Eli Casdin, the managing member of Casdin and the GP. F1 · ownership.direct: Received in exchange for 10,132,005 shares of common stock of SomaLogic, Inc. ("SomaLogic") pursuant to the Agreement and Plan of Merger (the "Merger Agreement"), dated October 4, 2023, by and among Standard BioTools Inc. (the "Company"), Martis Merger Sub, Inc. and SomaLogic (the "Merger"). Per the terms of the Merger, each share of SomaLogic common stock was converted into the right to receive 1.11 shares of the Company's common stock (the "Exchange Ratio") at the effective time of the Merger (the "Effective Time"). The securities are owned directly by Casdin Partners Master Fund, L.P. (the "Master Fund") and may be deemed to be indirectly beneficially owned by (i) Casdin Capital, LLC, the investment adviser to the Master Fund ("Casdin"), (ii) Casdin Partners GP, LLC, the general partner of the Master Fund (the "GP"), and (iii) Eli Casdin, the managing member of Casdin and the GP. Read SEC document |
| May 19, 2023 Filed May 20, 2023 01:00 UTC | STANDARD BIOTOOLS INC. LAB · Entity 6116 | PurchaseCommon Stock | 800,000 | $2.29 | $1,835,920.00 |
DisclosureSEC source: 0000919574-23-003425 · ownership.xml · nonDerivative · entry 3 Casdin Partners Master Fund, L.P. · CIK 0001534265 · Director · 10% owner Casdin Capital, LLC · CIK 0001534261 · Director · 10% owner Casdin Partners GP, LLC · CIK 0001534260 · Director · 10% owner Casdin Private Growth Equity Fund II, L.P. · CIK 0001891102 · Director Casdin Private Growth Equity Fund II GP, LLC · CIK 0001919480 · Director Casdin Partners FO1-MSV, LP · CIK 0001938709 · Director Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · See footnote Disclosed balance after: 1,200,000 F4 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions within the range of $2.29 to $2.2982. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in this footnote. F2 · ownership.nature: The securities are owned directly by Casdin Partners FO1-MSV, LP ("Casdin FO1") and may be deemed to be indirectly beneficially owned by (i) Casdin Capital, LLC, the investment adviser to Casdin FO1, (ii) Casdin Partners GP, LLC, the general partner of Casdin FO1, and (iii) Eli Casdin, the managing member of Casdin Capital, LLC and Casdin Partners GP, LLC. Read SEC document |
| May 18, 2023 Filed May 20, 2023 01:00 UTC | STANDARD BIOTOOLS INC. LAB · Entity 6116 | PurchaseCommon Stock | 150,000 | $2.16 | $323,865.00 |
DisclosureSEC source: 0000919574-23-003425 · ownership.xml · nonDerivative · entry 2 Casdin Partners Master Fund, L.P. · CIK 0001534265 · Director · 10% owner Casdin Capital, LLC · CIK 0001534261 · Director · 10% owner Casdin Partners GP, LLC · CIK 0001534260 · Director · 10% owner Casdin Private Growth Equity Fund II, L.P. · CIK 0001891102 · Director Casdin Private Growth Equity Fund II GP, LLC · CIK 0001919480 · Director Casdin Partners FO1-MSV, LP · CIK 0001938709 · Director Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · See footnote Disclosed balance after: 400,000 F3 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions within the range of $2.1489 to $2.1759. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in this footnote. F2 · ownership.nature: The securities are owned directly by Casdin Partners FO1-MSV, LP ("Casdin FO1") and may be deemed to be indirectly beneficially owned by (i) Casdin Capital, LLC, the investment adviser to Casdin FO1, (ii) Casdin Partners GP, LLC, the general partner of Casdin FO1, and (iii) Eli Casdin, the managing member of Casdin Capital, LLC and Casdin Partners GP, LLC. Read SEC document |
| May 17, 2023 Filed May 20, 2023 01:00 UTC | STANDARD BIOTOOLS INC. LAB · Entity 6116 | PurchaseCommon Stock | 250,000 | $1.89 | $471,550.00 |
DisclosureSEC source: 0000919574-23-003425 · ownership.xml · nonDerivative · entry 1 Casdin Partners Master Fund, L.P. · CIK 0001534265 · Director · 10% owner Casdin Capital, LLC · CIK 0001534261 · Director · 10% owner Casdin Partners GP, LLC · CIK 0001534260 · Director · 10% owner Casdin Private Growth Equity Fund II, L.P. · CIK 0001891102 · Director Casdin Private Growth Equity Fund II GP, LLC · CIK 0001919480 · Director Casdin Partners FO1-MSV, LP · CIK 0001938709 · Director Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · See footnote Disclosed balance after: 250,000 F1 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions within the range of $1.855 to $1.9237. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in this footnote. F2 · ownership.nature: The securities are owned directly by Casdin Partners FO1-MSV, LP ("Casdin FO1") and may be deemed to be indirectly beneficially owned by (i) Casdin Capital, LLC, the investment adviser to Casdin FO1, (ii) Casdin Partners GP, LLC, the general partner of Casdin FO1, and (iii) Eli Casdin, the managing member of Casdin Capital, LLC and Casdin Partners GP, LLC. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.